Viatris targets more than $50 million in Pacira deal synergies
Viatris said on its Nov. 5 third-quarter earnings call that it is targeting more than $50 million in annual savings from the pending Pacira transaction by the end of 2028. The proposed acquisition is valued at $1.65 billion and would add Pacira’s pain medicines to Viatris’ portfolio. Viatris also described low- to mid-single-digit Greater China growth as its 2027 outlook.
Why it matters
The deal remains subject to closing conditions, with completion expected by the end of November 2026, so the savings target has not yet been realized. Viatris expects the transaction to add Pacira’s existing revenue and adjusted EBITDA while integration proceeds.
Key facts
- 1Viatris would pay $36.50 per Pacira share in a cash transaction. tokenpost.com
- 2Pacira’s EXPAREL and ZILRETTA products would join Viatris’ portfolio. tokenpost.com
- 3Pacira generated $746 million in revenue and $177 million in adjusted EBITDA during the 12 months ended June 30, 2026. tokenpost.com
- 4Greater China net sales were $702.6 million for the quarter ended Sept. 30, versus $615.2 million in the year-earlier quarter; reported growth was 14% and operational growth excluding currency was 10%. tokenpost.com
- 5The acquisition is expected to close by the end of November 2026, subject to closing conditions. tokenpost.com
Open questions
- Viatris provided no estimate for additional savings beyond the more than $50 million annual target.
- The Greater China growth outlook was given during the earnings-call question-and-answer session and was not included in Viatris’ written earnings release or presentation.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.